UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

VizWiz Grand Challenge: Answering Visual Questions from Blind People

2018 IEEE/CVF Conference on Computer Vision and Pattern Recognition, 2018, p.3608-3617

2018

Volltextzugriff (PDF)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

The Lancet (British edition), 2020-05, Vol.395 (10236), p.1569-1578

2020

Volltextzugriff (PDF)

t.b.c._Kolonialzeitliche Kunst in symmetrischer Perspektive: Julius Lips und die Inversion des Blicks

Brus, Anna

1, 2025

Volltextzugriff (PDF)

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

The Lancet (British edition), 2021-07, Vol.398 (10296), p.213-222

2021

Volltextzugriff (PDF)

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Nature medicine, 2021-10, Vol.27 (10), p.1752-1760

2021

Volltextzugriff (PDF)

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

The Lancet (British edition), 2019-07, Vol.394 (10193), p.121-130

2019

Volltextzugriff (PDF)

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1940-1948

2019

Volltextzugriff (PDF)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2021-07, Vol.398 (10295), p.143-155

2021

Volltextzugriff (PDF)

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2020-09, Vol.396 (10253), p.759-769

2020

Volltextzugriff (PDF)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-06, Vol.401 (10391), p.1853-1865

2023

Volltextzugriff (PDF)

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

The Lancet (British edition), 2020-12, Vol.396 (10266), p.1895-1904

2020

Volltextzugriff (PDF)

Blind Image Quality Assessment Using a Deep Bilinear Convolutional Neural Network

IEEE transactions on circuits and systems for video technology, 2020-01, Vol.30 (1), p.36-47

2020

Volltextzugriff (PDF)

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

The Lancet (British edition), 2022-04, Vol.399 (10333), p.1383-1390

2022

Volltextzugriff (PDF)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

The Lancet infectious diseases, 2021-06, Vol.21 (6), p.803-812

2021

Volltextzugriff (PDF)

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

The lancet oncology, 2020-04, Vol.21 (4), p.519-530

2020

Volltextzugriff (PDF)

Die Augen der Avantgarden: Von der Macht der Blicke in der Moderne

Schmidt-Burkhardt, Astrit

1, 2024

Volltextzugriff (PDF)

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2369-2379

2020

Volltextzugriff (PDF)

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-12, Vol.390 (10111), p.2461-2471

2017

Volltextzugriff (PDF)

Zündkern Messianischen Augenblicks: Der Analogische Kairos Bloch, Rosenzweig, Heidegger und Die Stätte der Philosophia Perennis

Huber, Albrecht

1, 2024

Volltextzugriff (PDF)

Partial recovery of visual function in a blind patient after optogenetic therapy

Nature Medicine, 2021-07, Vol.27 (7), p.1223-1229

2021

Volltextzugriff (PDF)

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

The Lancet (British edition), 2023-05, Vol.401 (10389), p.1655-1668

2023

Volltextzugriff (PDF)

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

The Lancet (British edition), 2021-03, Vol.397 (10278), p.971-984

2021

Volltextzugriff (PDF)

1 – 25 von 7.463.725

Suche als RSS-Feed

Aktive Filter

ThemaAdult

ThemaMedicine & Public Health

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.853.518)
Mit Volltextzugriff
(5.447.151)

Publikationsform

Artikel
(4.628.096)
Buchkapitel
(804.295)
magazinearticle
(621.594)
Dissertationen
(477.239)
Reviews
(296.724)
Newsletter-Artikel
(224.407)
Zeitungsartikel
(192.111)
Tagungsberichte
(90.125)
Bücher
(59.895)
Texte
(30.208)
Referenzeintrag
(21.693)
Berichte
(16.025)
Webseiten
(722)
Datensätze
(405)
government_documents
(49)
videos
(43)
Zeitschriften
(31)
Bilder
(15)
Sonstige
(15)
market_researchs
(12)

15 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(6.818.471)
Deutsch
(561.526)
Japanisch
(342.309)
Spanisch
(53.810)
Portugiesisch
(44.512)
Französisch
(41.657)
Niederländisch
(30.525)
Polnisch
(21.585)
Norwegisch
(18.690)
Italienisch
(13.907)
Russisch
(8.741)
Chinesisch
(7.769)
Türkisch
(6.956)
Croatian
(6.854)
Dänisch
(6.100)
Serbian
(5.121)
Tschechisch
(5.023)
Bokmål, Norwegian; Norwegian Bokmål
(4.694)
Slowenisch
(4.555)
Slowakisch
(3.098)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.271.338)
Life Sciences & Biomedicine
(1.731.007)
Humans
(940.392)
Social Sciences
(464.585)
Male
(415.912)
Animals
(404.194)
Female
(400.618)
Technology
(341.379)
Physical Sciences
(306.596)
Biological And Medical Sciences
(293.168)
Medical Sciences
(205.828)
Neurosciences & Neurology
(197.962)
Arts & Humanities
(179.823)
Neurosciences
(175.967)
Engineering
(173.934)
Patients
(173.808)
Psychology
(159.036)
Science & Technology - Other Topics
(144.725)
Middle Aged
(143.925)
Studies
(143.130)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(1.765.710)
IngentaConnect Journals
(1.722.572)
MEDLINE
(1.270.284)
Nexis Uni
(1.024.175)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(1.013.500)
IngentaConnect Journals
(1.002.077)
Publisher or Other Site
(880.142)
Ebook Central Perpetual and DDA
(693.975)
eBooks on EBSCOhost
(664.991)
Wiley Online Library Journals
(616.287)
Elsevier ScienceDirect Journals Complete
(500.647)
JSTOR
(485.526)
BSC - Ebsco (Business Source Ultimate)
(481.456)
ProQuest Dissertations & Theses A&I
(476.729)
Wiley Online Library
(449.427)
Springer journals
(427.280)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(326.294)
Taylor & Francis Journals Collection
(295.989)
Taylor & Francis Online Single Subscriptions
(288.009)
Taylor & Francis Online
(278.248)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Pr Newswire
(71.136)
The Spectator
(56.582)
Billboard
(54.080)
Plos One
(47.091)
Business Wire
(35.401)
Scientific Reports
(28.234)
M2 Presswire
(27.946)
Daily Herald
(26.183)
The Hollywood Reporter
(22.772)
Maclean's
(20.598)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

VizWiz Grand Challenge: Answering Visual Questions from Blind People

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

t.b.c._Kolonialzeitliche Kunst in symmetrischer Perspektive: Julius Lips und die Inversion des Blicks

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Blind Image Quality Assessment Using a Deep Bilinear Convolutional Neural Network

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Die Augen der Avantgarden: Von der Macht der Blicke in der Moderne

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Zündkern Messianischen Augenblicks: Der Analogische Kairos Bloch, Rosenzweig, Heidegger und Die Stätte der Philosophia Perennis

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Partial recovery of visual function in a blind patient after optogenetic therapy

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Aktive Filter

Suchergebnisse filtern